A boardroom shake-up at Novo Nordisk has handed unprecedented power to its top shareholder, the Novo Nordisk Foundation, ...

Shares of Novo Nordisk fell around 3% on Wednesday, extending their losses from a day earlier, after the Wegovy maker's top ...

In the latest close session, Novo Nordisk (NVO) was down 1.59% at $52.05. The stock trailed the S&P 500, which registered a daily gain of 0.23%. On the other hand, the Dow registered a gain of 0.34%, ...

Some investors may welcome the Novo Nordisk Foundation’s sweeping moves to accelerate a strategy shift. Yet the speed and ...

Sure, Eli Lilly’s Tirzepatide-based drugs have caught up significantly to Novo Nordisk’s semaglutide-based ones. As a result, ...

Novo Nordisk (($NVO)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a study titled ‘Safety, ...

Get the latest on Novo Nordisk's Alzheimer's trial, stock outlook, and market risks. See what investors need to know before ...

The chairman of Novo Nordisk and six other independent board members quit on Tuesday after a dispute with the company's ...

Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as ...

The changing of the guard at Novo Nordisk took another turn this week as the company revealed that seven members of its board ...

Karen Finerman, CEO & Co-founder, Metropolitan Capital Advisors, said in a recent program on CNBC that she likes NVO amid the ...

Under the agreement, Novo Nordisk will be granted exclusive global rights to develop and commercialize zaltenibart.